| Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding |
The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive:
|
|
|
|
|
December 31,
|
|
|
|
|
|
|
2019
|
|
|
2018
|
|
|
Warrants to purchase Series C-1 Preferred
|
|
|
|
|
—
|
|
|
|
14,033
|
|
|
Warrants to purchase common stock associated with Solar loan agreement
|
|
|
|
|
122,435
|
|
|
|
122,435
|
|
|
Warrants to purchase common stock associated with June 2016 public offering
|
|
|
|
|
4,218,750
|
|
|
|
4,218,750
|
|
|
Warrants to purchase common stock associated with March 2018 Public Offering - Series 1
|
|
|
|
|
—
|
|
|
|
13,198,075
|
|
|
Warrants to purchase common stock associated with March 2018 Public Offering - Series 2
|
|
|
|
|
7,988,175
|
|
|
|
7,988,175
|
|
|
Outstanding stock options
|
|
|
|
|
5,261,860
|
|
|
|
4,052,913
|
|
|
Outstanding restricted stock units
|
|
|
|
|
966,394
|
|
|
|
111,891
|
|
|
Common stock associated with 6% convertible senior notes
|
|
|
|
|
11,382,000
|
|
|
|
—
|
|
|
Warrants to purchase common stock associated with December 2019 Public Offering
|
|
|
|
|
44,722,222
|
|
|
|
—
|
|
|
Option to purchase common stock associated with December 2019 Public Offering
|
|
|
|
|
5,833,333
|
|
|
|
—
|
|
|
Total
|
|
|
|
|
80,495,169
|
|
|
|
29,706,272
|
|
|